İbrahim DOĞAN, Barış ESER, Sultan ÖZKURT, Özlem YAYAR, Bülent ÖZGÜR, Hüseyin KAYADİBİ, Tolga DOĞAN, Ahmet MUŞMUL, Mehmet SOYDAN

Serum ADMA, endothelial dysfunction, and atherosclerosis in hypervolemic hemodialysis patients

Background/aim: Asymmetric dimethyl arginine (ADMA) is a strong predictor of cardiovascular disease and mortality in patients under hemodialysis treatment. We aimed to investigate the relationship among volume status, endothelial dysfunction, and ADMA in hemodialysis patients. Materials and methods: A total of 120 patients with a history of hemodialysis treatment were included. ADMA and CRP were measured. Echocardiographic evaluation and carotid artery intima-media thickness (CIMT) measurements were performed. Patients were divided into two groups according to clinical evaluation, ultrafiltration rate, vena cava inferior diameter (VCI), and cardiothoracic index (CTI); the two groups were hypervolemic and normovolemic. Results: The hypervolemic group included 61 patients while the normovolemic group included 59 patients. CIMT was higher in the hypervolemic group, but this result was not statistically significant (0.95 mm versus 0.85 mm, P = 0.232). There was a statistically significant difference between the hypervolemic and normovolemic groups in terms of ADMA (P < 0.001) (0.69 ± 0.57 μmol/L and 0.41 ± 0.04 μmol/L, respectively). Positive correlations were observed between serum ADMA, VCI, CTI, CRP, CIMT, and cardiac mass (P < 0.001, P = 0.016, P < 0.001, P = 0.006, P = 0.022, respectively), and negative correlations were observed between ADMA and ejection fraction and albumin (P = 0.024, P = 0.024, respectively). In multiple linear regression analysis, ADMA was independently associated with age, systolic blood pressure, CTI, and volume status. Conclusion: ADMA may be a potential determinant of hypervolemia as well as atherosclerosis in patients under hemodialysis treatment.

Keywords:

Asymmetric dimethyl arginine, atherosclerosis, endothelial dysfunction, hemodialysis, hypervolemia,

PDF

___

Kalantar-Zadeh K, Regidor DL, Kovesdy CP, Van WD, Bunnapradist S, Horwich TB, Fonarow GC. Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis. Circulation 2009; 119: 671-679.
Muntner, JH, Astor BC, Folsom AR, Coresh J. Traditional and nontraditional risk factors predict coronary heart disease in chronic kidney disease: results from the Atherosclerosis Risk in Communities study. J Am Soc Nephrol 2005; 16: 529-538.
Agarwal R. Hypervolemia is associated with increased mortality among hemodialysis patients. Hypertension 2010; 56: 512-517.
Foley RN, Herzog CA, Collins AJ. Blood pressure and long- term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study. Kidney Int 2002; 62: 1784-1790.
Saran R, Bragg-Gresham JL, Levin NW, Twardowski ZJ, Wizemann V, Saito A, Kimata N, Gillespie BW, Combe C, Bommer J et al. Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS. Kidney Int 2006; 69: 1222–1228.
Tetsuka T, Ando Y, Ono S, Asano Y. Change in inferior vena caval diameter detected by ultrasonography during and after hemodialysis. ASAIO J 1995; 41: 105-110.
Yashiro M, Kamata T, Yamadori N, Tomita M, Muso E. Evaluation of markers to estimate volume status in hemodialysis patients: atrial natriuretic peptide, inferior vena cava diameter, blood volume changes and filtration coefficients of microvasculature. Ther Apher Dial 2007; 11: 131-137.
Lieb W, Benndorf RA, Benjamin EJ, Sullivan LM, Maas R, Xanthakis V, Schwedhelm E, Aragam J, Schulze F, Böger RH et al. Plasma asymmetric dimethylarginine, L-arginine, and left ventricular structure and function in a community-based sample. Atherosclerosis 2009; 204: 282-287.
Shafi T, Hostetter TH, Meyer TW, Hwang S, Hai X, Melamed ML, Banerjee T, Coresh J, Powe NR. Serum asymmetric and symmetric dimethylarginine and morbidity and mortality in hemodialysis patients. Am J Kidney Dis 2017; 70: 48-58.
Sahn DJ, De Maria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-1083.
Shin SJ, Kim HW, Chung S, Chung HW, Lee SJ, Kim YS, Bang BK, Chang YS, Park CW. Late referral to a nephrologist increases the risk of uremia related cardiac hypertrophy in patients on hemodialysis. Nephron Clin Pract 2007; 107: 139-146.
Glassock RJ, Pecoits-Filho R, Barberato SH. Left ventricular mass in chronic kidney disease and ESRD. Clin J Am Soc Nephrol 2009; 4: 79-91.
Agarwal R. Interdialytic hypertension: an update. Adv Chronic Kidney Dis 2011; 18: 11-16.
London GM, Marchais SJ, Guerin AP, Metivier F, Pannier B. Cardiac hypertrophy and arterial alteration in end-stage renal disease. Hemodynamic factors. Kidney Int 1993; 43: 42-49.
Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frolich J et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001; 358: 2113-2117.
Ozkahya M, Ok E, Cirit M, Aydin S, Akcicek F, Basci A, Dorhout Mees EJ. Regression of left ventricular hypertrophy in hemodialysis patients by ultrafiltration and reduced salt intake without antihypertensive drugs. Nephrol Dial Transplant 1998; 13: 1489-1493.
de Castro Júnior JR, Fernandes N, Lacet TB, Maia FS, Bonato GR, Nogueira C, Barberato SH, de Paula RB. Total body water reduction in subjects with chronic kidney disease on peritoneal dialysis is associated with a better hypertension control. J Bras Nefrol 2014; 36:482-489.
Ozturk S, Karadag S, Yegen M, Gursu M, Uzun S, Aydin Z, Gurdal A, Koldas M, Kumbasar B, Kazancioglu R. The relationship of plasma ADMA levels with cardiac functions and metabolic parameters in peritoneal dialysis patients. Clin Exp Nephrol 2013; 17: 431-436.
Stenvinkel P, Carrero JJ, Axelsson J, Lindholm B, Heimburger O, Massy Z. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? Clin J Am Soc Nephrol 2008; 3: 505- 5221.
Furuki K, Adachi H, Matsuoka H, Enomoto M, Satoh A, Hino A, Hirai Y, Imaizumi T. Plasma levels of asymmetric dimethylarginine (ADMA) are related to intima–media thickness of the carotid artery: an epidemiological study. Atherosclerosis 2007; 191: 206-210.
Zoccali C, Benedetto FA, Renkemaas, Mallamaci F, Tripepi G, Malatino LS, Böger R; CREED Investigators. Asymmetric dimethylarginine, C-reactive protein, and carotid intima– media thickness in end-stage renal disease. J Am Soc Nephrol 2002; 13: 490-496.
Zoccali C, Mallamaci F, Maas R. Left ventricular hypertrophy cardiac remodeling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int 2002; 62: 339- 345.
London GM, Guerin AP, Marchais SJ, Pannier B, Safar ME, Day M, Metivier F. Cardiac and arterial interactions in end- stage renal disease. Kidney Int 1996; 50: 600-608.
Avci E, Coskun S, Cakir E, Kurt Y, Ozgur Akgul E, Bilgi C. Relations between concentrations of asymmetric dimethylarginine and neopterin as potential risk factors for cardiovascular diseases in haemodialysis-treated patients. Ren Fail 2008; 30: 784-790.
Allawi AAD. Malnutrition, inflammation, and atherosclerosis (MIA syndrome) in patients with end-stage renal disease on maintenance hemodialysis (a single centre experience). Diabetes Metab Syndr 2017; 17: 302-308.
Kuhlencordt PJ, Gyurko R, Han F, Scherrer-Crosbie M, Aretz TH, Hajjar R, Picard MH, Huang PL. Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knock-out mice. Circulation 2001; 104:448-454.
Hattler BG, Oddis CV, Zeevi A, Luss H, Shah N, Geller DA, Billiar TR, Simmons RL, Finkel MS. Regulation of constitutive nitric oxide synthase activity by the human heart. Am J Cardiol 1995; 76: 957-959.